BioCryst Pharmaceuticals
BCRX
BCRX
233 hedge funds and large institutions have $2.09B invested in BioCryst Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 67 increasing their positions, 71 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
13% more funds holding
Funds holding: 206 → 233 (+27)
3.21% more ownership
Funds ownership: 66.01% → 69.22% (+3.2%)
6% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 71
Holders
233
Holding in Top 10
6
Calls
$92M
Puts
$34.8M
Top Buyers
| 1 | +$73.5M | |
| 2 | +$61.7M | |
| 3 | +$50.4M | |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$37.7M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$30.5M |
Top Sellers
| 1 | -$43.1M | |
| 2 | -$34.9M | |
| 3 | -$20.9M | |
| 4 |
Two Sigma Investments
New York
|
-$16.7M |
| 5 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$14.7M |